CEBPA and acute myeloid leukemia: Consistent with previous studies, FLT3-ITD mutations predicted a high likelihood of relapse and worse survival through univariate analysis in AML patients (did not receive FLT3 inhibitors) with CEBPAbZIP-inf mutations or with biallelic CEBPA mutations [6,24].